0000899243-15-000779.txt : 20150707 0000899243-15-000779.hdr.sgml : 20150707 20150707160611 ACCESSION NUMBER: 0000899243-15-000779 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150703 FILED AS OF DATE: 20150707 DATE AS OF CHANGE: 20150707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eleven Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 252025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-9911 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCCABE JOHN J CENTRAL INDEX KEY: 0001205535 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 15976658 MAIL ADDRESS: STREET 1: C/O ELEVEN BIOTHERAPEUTICS, INC. STREET 2: 215 FIRST STREET, SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2015-07-03 0 0001485003 Eleven Biotherapeutics, Inc. EBIO 0001205535 MCCABE JOHN J C/O ELEVEN BIOTHERAPEUTICS, INC. 215 FIRST STREET, SUITE 400 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Stock Option (Right to Buy) 0.76 2022-05-17 Common Stock 21496 D Stock Option (Right to Buy) 0.83 2023-02-13 Common Stock 3937 D Stock Option (Right to Buy) 7.37 2023-10-30 Common Stock 10236 D Stock Option (Right to Buy) 10.40 2025-02-25 Common Stock 24500 D Stock Option (Right to Buy) 3.10 2025-05-20 Common Stock 24500 D This option was granted on May 17, 2012 for 31,496 shares and vests over four years, with 25% of the shares underlying the option vesting on April 23, 2013 and an additional 6.25% of the shares underlying the option vesting at the end of each three-month period thereafter. This option was granted on February 14, 2013 and vests over four years, with 6.25% of the shares underlying the option vesting quarterly after January 1, 2013. This option was granted on October 31, 2013 and vests over four years, with 6.25% of the shares underlying the option vesting quarterly after October 1, 2013. This option was granted on February 26, 2015 and vests over four years, with 1/16th of the shares underlying the option vesting at the end of each successive three-month period after January 1, 2015. This option was granted on May 21, 2015 and vests over two years, with 1/24th of the shares underlying the option vesting at the end of each successive one-month period after May 21, 2015. Vice President of Finance and Business Operations Exhibit Index Exhibit 24.1 - Power of Attorney /s/ John J. McCabe 2015-07-07 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                                                                    Exhibit 24.1

         LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

      Know all by these presents, that the undersigned hereby makes, constitutes
and appoints Abbie C. Celniker, Ph.D., as the undersigned's true and lawful
attorney-in-fact, with full power and authority as hereinafter described to:

      (1)   execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of, and/or holder of equity in, Eleven
Biotherapeutics, Inc., a Delaware corporation (the "Company"), Forms 3, 4, and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

      (2)   do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to prepare, complete and execute any such
Form 3, 4, or 5, prepare, complete and execute any amendment or amendments
thereto, and timely deliver and file such form with the United States Securities
and Exchange Commission (the "SEC") and any stock exchange or similar authority,
including without limitation the filing of a Form ID or any other application
materials to enable the undersigned to gain or maintain access to the Electronic
Data Gathering Analysis and Retrieval System of the SEC;

      (3)   seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information regarding transactions in the Company's
securities from any third party, including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release any such information to such attorney-in-fact and approves and
ratifies any such release of information; and

      (4)   take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

      The undersigned hereby grants to the attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming nor
relieving, nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.  The undersigned
acknowledges that neither the Company nor the foregoing attorney-in-fact assumes
(i) any liability for the undersigned's responsibility to comply with the
requirements of the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any obligation or liability
of the undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorney-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 7th day of July, 2015.


                                            /s/ John J. McCabe
                                            ----------------------------------
                                            John J. McCabe